These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16762726)

  • 1. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity.
    Clynes R
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):585-612. PubMed ID: 16762726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bi-specific antibody therapy for the treatment of cancer.
    Withoff S; Helfrich W; de Leij LF; Molema G
    Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc-receptors as regulators of immunity.
    Nimmerjahn F; Ravetch JV
    Adv Immunol; 2007; 96():179-204. PubMed ID: 17981207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies, Fc receptors and cancer.
    Nimmerjahn F; Ravetch JV
    Curr Opin Immunol; 2007 Apr; 19(2):239-45. PubMed ID: 17291742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.
    DiLillo DJ; Ravetch JV
    Cancer Immunol Res; 2015 Jul; 3(7):704-13. PubMed ID: 26138698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative signaling in Fc receptor complexes.
    Daëron M; Lesourne R
    Adv Immunol; 2006; 89():39-86. PubMed ID: 16682272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.
    Desjarlais JR; Lazar GA; Zhukovsky EA; Chu SY
    Drug Discov Today; 2007 Nov; 12(21-22):898-910. PubMed ID: 17993407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc receptors: role in biology and antibody therapy.
    van de Winkel JG
    Immunol Lett; 2010 Jan; 128(1):4-5. PubMed ID: 19808048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms].
    Oka Y; Tsuboi A; Sugiyama H
    Tanpakushitsu Kakusan Koso; 2003 Aug; 48(11 Suppl):1663-70. PubMed ID: 12931627
    [No Abstract]   [Full Text] [Related]  

  • 17. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models.
    Sadun RE; Hsu WE; Zhang N; Nien YC; Bergfeld SA; Sabzevari H; Lutsiak ME; Khawli L; Hu P; Epstein AL
    J Immunother; 2008 Apr; 31(3):235-45. PubMed ID: 18317364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyzing antibody-Fc-receptor interactions.
    Nimmerjahn F; Ravetch JV
    Methods Mol Biol; 2008; 415():151-62. PubMed ID: 18370153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.
    Barnhart BC; Quigley M
    Immunol Cell Biol; 2017 Apr; 95(4):340-346. PubMed ID: 27974746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.
    Nakamura A; Kubo T; Takai T
    Adv Exp Med Biol; 2008; 640():220-33. PubMed ID: 19065795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.